These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21235718)

  • 1. Intermittent androgen suppression in prostate cancer: testosterone levels and its implication.
    Mearini L; Zucchi A; Costantini E; Bini V; Porena M
    J Sex Med; 2011 Apr; 8(4):1218-27. PubMed ID: 21235718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
    Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
    J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
    Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
    Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M; Goldenberg SL; Bhagirath K; Gleave M
    Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
    J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent Complete Androgen Blockade in Metastatic Prostate Cancer.
    Rambeaud J
    Eur Urol; 1998 Dec; 35 Suppl S1():32-36. PubMed ID: 9858850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.
    Spry NA; Kristjanson L; Hooton B; Hayden L; Neerhut G; Gurney H; Corica T; Korbel E; Weinstein S; McCaul K
    Eur J Cancer; 2006 May; 42(8):1083-92. PubMed ID: 16632343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
    Malone S; Perry G; Segal R; Dahrouge S; Crook J
    BJU Int; 2005 Sep; 96(4):514-20. PubMed ID: 16104902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
    Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
    Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
    Gleave M; Santo N; Rennie PS; Goldenberg SL; Bruchovsky N; Sullivan LD
    Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
    Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
    Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up.
    Goldenberg SL; Gleave ME; Taylor D; Bruchovsky N
    Mol Urol; 1999; 3(3):287-292. PubMed ID: 10851335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
    Tunn UW; Canepa G; Kochanowsky A; Kienle E
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent androgen suppression in the management of prostate cancer.
    Crook JM; Szumacher E; Malone S; Huan S; Segal R
    Urology; 1999 Mar; 53(3):530-4. PubMed ID: 10096379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
    Mottet N; Lucas C; Sene E; Avances C; Maubach L; Wolff JM
    Urol Int; 2005; 75(3):204-8. PubMed ID: 16215305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.